RxDoctor Payments Data

Mostafa Ghanim, MD

Cardiovascular Disease · Ottawa, ILNPI 1598118895

Payments from drug & device makers

$5,303in general payments, 2019–2025

Across 101 payments — averaging $52.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Abbott$741
  • Siemens Medical Solutions USA, Inc.$665
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$465
  • Abiomed$388
  • AstraZeneca$198
  • plus $446 from 8 others

What the payments were for

  • Travel & lodging$2,23842%
  • Food & beverage$2,78052%
  • Education$2855%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,303 in reported general payments places this provider in the 70th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$157,157
Medicare patients
1,412
Services billed
2,998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$82,971
EntrestoSacubitril/Valsartan18$25,826
XareltoRivaroxaban14$17,921
Metoprolol Succinate142$2,071
Diltiazem 12hr ErDiltiazem Hcl14$1,925
Atorvastatin Calcium132$1,534
ClopidogrelClopidogrel Bisulfate81$970
Losartan Potassium105$940
Carvedilol59$633
Rosuvastatin Calcium23$572
Torsemide34$524
Ezetimibe12$466
Amlodipine Besylate53$398
Warfarin Sodium40$381
Furosemide86$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$21$25,82618 claims
Johnson & JohnsonXarelto$55$17,92114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Ottawa

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →